Table 1

Characteristics of t(8;21) AML

CharacteristicRisk directedNot risk directed
Low risk—chemo (n = 29)High risk—HSCT (n = 40)TotalLow risk—HSCT (n = 18)High risk—Chemo (n = 29)TotalP
Age (years)28 (15-56)37 (15-54)33 (15-56)35 (16-54)37 (15-60)36 (15-60)NS
Gender (male/female)16/1626/1439/3012/616/1328/19NS
WBC (109/L)5.4 (1.4-79)9.0 (1.9-59)8.1 (1.4-79)6.0 (1.2-30)8.0 (2.5-80.5)7.2 (1.2-80.5)NS
HGB (g/L)83 (34-136)81 (49-133)81(45-136)95 (41-123)74 (34-135)78 (34-135)NS
PLT (109/L)37 (5-286)27 (4-108)32.5 (4-286)33 (2-106)35 (7-225)34 (2-225)NS
Blasts in BM (%)52 (26-89)51 (20-86)52(20-89)56 (21-82)39 (24-92)46 (21-92)NS
RUNX1-RUNX1T1 (%)506 (353-993)411(97-1082)439 (35-1082)422 (98-848)358(52-1163)380 (43-1163)NS
KIT mutation (%)17.6(3/17)54.8(17/31)54.8(20/48)50(5/10)34.6(9/26)38.9(14/36)NS
Comorbidity score (0/1-2/3)*23/17/018/11/041/28/016/13/011/7/027/20/0NS
  • There are no differences in the characteristics between the low riskchemotherapy group and the low riskHSCT group and between the high riskchemotherapy group and the high riskHSCT group. HGB, hemoglobin; PLT, platelet; BM, bone marrow; NS, not significant.

  • * According to the Charlson Comorbidity Index.